A one-year quality improvement (QI) project implemented and standardized comprehensive biomarker testing in patients with metastatic non-small cell lung cancer (NSCLC). Custom data reports and monitoring dashboards ensured practice-wide adoption and sustainability across multiple clinic sites. After increasing biomarker testing rates from 68% to 92.7%, this QI project is now being scaled across the country through the US Oncology Network, McKesson as a best-practice initiative.
Nearly 70% of the positive biomarkers will have an impact on a patient’s first line treatment selection.
